Factors Associated With HIV Prevalence Among A Canadian Clinical Cohort Of Transgender Women



Lacombe-Duncan, A., Persad, Y., Shokoohi, M., Underhill, A., Machouf, N., Côté, P., Wheatley, M., Gupta, M., Kyne, L.T., Besharati, A.A., Chan, L.Y.L., Hranilovic, S., Bourns, A., Nguyen, Q., & Loutfy, M. 31st Annual Canadian Conference on HIV/AIDS Research April 27th-29th, 2022

Study Rationale, Aims, and Methods

Rationale

• HIV prevalence data among transgender (trans) people are lacking in Canada, which may contribute to gender-based inequities in the HIV response.

Aims

• To examine a) HIV prevalence and b) associated factors among trans women engaged in clinical care in Toronto, Ontario and Montreal, Quebec, Canada.

Methods

- Retrospective chart review
- Collected sociodemographic and clinical characteristics, including HIV prevalence data from:
 - Trans women
 - Aged 16 years or older
 - Accessing health care at one or more of six family medicine and/or HIV clinics in Montreal and Toronto, Canada *excluded patients only seen at endocrinology clinic
- Between July 2018 and December 2019
- Prevalence of HIV reported overall and then compared across sociodemographic and clinical subgroups using univariate and multivariate logistic regression analyses

Results: HIV Prevalence & Associated Sociodemographic Factors

	n/%
HIV negative	599 (40.1%)
HIV positive	86 (5.8%)
Missing	810 (54.2%)

- Sociodemographic factors statistically significantly associated with HIV prevalence among trans women in multivariate analyses:
 - Age: 50+ vs. < 30 years, aOR: 2.52, 95% CI: 1.10, 5.81
 - Race/ethnicity: Black vs. white, aOR: 4.35, 95% CI: 1.41, 13.43
 - Immigration status: Landed immigrant/permanent resident vs. Canadian citizen: aOR: 5.76, 95% CI: 1.54, 21.42
 - Source of income: Receiving social assistance vs. not, aOR: 4.63, 95% CI: 1.43, 14.93
- Not statistically significant: birthplace, relationship status

Results: Associated Clinical Factors and Study Implications

- Clinical factors statistically significantly associated with HIV prevalence among trans women in multivariate analyses:
 - Ever using recreational drugs vs. never, aOR: 3.95, 95% 1.19, 13.06
 - History of hepatitis B vs. no history, aOR: 4.44, 95% CI: 1.12, 16.75
- Not statistically significant: cigarette history, history of injection drug use, history of sex work, history of hepatitis C

Implications:

- Prevalence of HIV was high at 7.5%, while lower than expected based on global estimates.
- Over one-third of patients did not have a documented HIV status, suggesting gaps in HIV testing.
- Findings highlight socioeconomic, psychosocial, and medical challenges among trans women that may be associated with HIV or represent experiences of trans women post HIV-diagnosis.
- Findings inform future HIV prevention programs and support opportunities for trans women in Canada.

TRANS WOMEN HIV RESEARCH INITIATIVE

We would like to thank everyone involved for their invaluable contributions to TWIRI. Thank you to...

MTTS team members;

All of the community members involved in TWIRI;

The Coordinators, Peer Research Associates, co-investigators, collaborators, students, & volunteers;

The partnering clinic and community-based organizational sites and partners

The TWIRI Community Advisory Board;

Our funders: Canadian Institutes of Health Research; The Innovation Fund of the Alternative Funding Plan for the Academic Health Sciences Centres of Ontario; Maple Leaf Research; and Gilead Inc.

Thank you! Questions?

Contact Ashley: <u>lacombed@umich.edu</u> or Yasmeen: <u>yasmeen.persad@wchospital.ca</u>







